Getinge announces today an agreement to acquire 100% of the
shares in FLUOPTICS SAS, a French based leader in fluorescence imaging as an
aid to surgery. The acquisition will expand Getinge’s customer offering in
clinical decision support by providing safe and improved operating efficiency.
FLUOPTICS,
based in Grenoble, France, was founded in 2009 and has since developed NIR
imaging systems, consisting of a dedicated camera and the related software, to
visualize the vascularization and other tissues by the use of a fluorescent
marker or by using the natural autofluorescence of the tissues. FLUOPTICS’s
solutions allows for visualizing physiological and biological phenomena that
are invisible to the naked eye.
“With the acquisition of FLUOPTICS, we are opening a new chapter
for our Surgical Workflows business by expanding into the field of advanced
visualization and decision support for surgeons,” says Stéphane Le Roy,
President Surgical Workflows. “We will create a unique ecosystem with surgical
lighting, fluorescence imaging and digital solutions for image processing and
management.”
The addressable global market is estimated to be more than SEK
2.5 B, recording an annual compounded average growth rate of 8 % during the
forecasted period. More than 380 institutions in US, Europe and Asia are currently
using the FLUOPTICS technology in their daily clinical routine with over 40,000
procedures performed. The development and the production will remain in
Grenoble and will, together with Getinge’s existing site in Ardon France, shape
Getinge’s Center of Excellence for Optics and Visualization.
“I am particularly happy to join forces with Getinge and our
team is eager to leverage its impressive international network to reach all
Operating Rooms in the world, “says Odile Allard, CEO of FLUOPTICS. “Together
with Getinge R&D and commercial teams, we are confident that FLUOPTICS will
be in the best position to accomplish our mission to establish a new standard
in fluorescence imaging in the Operating Room”.
Getinge will, via its subsidiary Getinge Infection Control SAS,
acquire all outstanding shares in Fluoptics and will pay approximately EUR 26 M
in cash on closing. Moreover, additional
earn-out may be paid if agreed milestones are achieved. The acquisition
will be financed through available cash. Getinge expects no material
integration costs. Until closing, Fluoptics will continue to operate as a
wholly independent third party.
The transaction is subject to, and conditional upon, foreign
direct investment approval in France and other specific closing conditions. The
transaction is expected to close before the end of the second quarter 2022.
No comments:
Post a Comment